NRG-GU008 / RGUP20037 / INNOVATE / Hong Zhang
Research Question:
How well does adding apalutamide, abiraterone acetate, and prednisone to the usual
hormone therapy and radiation therapy work compared to the usual hormone therapy and
radiation therapy in treating patients with node-positive prostate cancer after surgery?
Basic Study Information
Purpose:
This phase III trial studies whether adding apalutamide to the usual treatment improves
outcome in patients with lymph node positive prostate cancer after surgery. Radiation
therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or
male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide,
may help stop or reduce the growth of prostate cancer cell growth by blocking the
attachment of androgen to its receptors on cancer cells, a mechanism similar to stopping
the entrance of a key into its lock. Adding apalutamide to the usual hormone therapy
and radiation therapy after surgery may stabilize prostate cancer and prevent it from
spreading and extend time without disease spreading compared to the usual approach.
Location: University of Rochester Medical Center
Study Reference #: RGUP20037
Lead Researcher (Principal Investigator)
Lead Researcher:
Hong Zhang
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search